Seven Ways Patients Get Hurt If Tianeptine Goes Into Schedule I

If you live with fibromyalgia, small fiber neuropathy, or chronic pain that's outlasted every first-line treatment your doctor had to offer, you already know what it feels like to lose an option. You've had a medication pulled, a specialist retire, an insurer deny a refill, and you've felt the specific dread of wondering what you're supposed to do now.

That dread is about to have a new source. DEA and HHS want to place tianeptine, an atypical antidepressant prescribed in over 60 countries, into Schedule I on August 7, 2026.

Not restricted. Not prescription-only. Illegal to possess, full stop, with no transition plan for the people already depending on it. Most coverage of this proposal focuses on the "gas station heroin" products that triggered it, the ones already illegal to lawfully market under existing FDA authority. What it leaves out is who actually gets hurt when a compound with completed human trials in fibromyalgia and post-mastectomy pain gets classified alongside heroin. That's the gap this piece is here to close.

Here's what we'll cover: the seven specific ways patients lose access, research momentum, and safety under this proposal, and what the comment record needs to hear before it closes.

1. People currently taking it lose access overnight, with no medical off-ramp.

Schedule I placement doesn't create a taper plan. On the effective date, people who have been taking tianeptine daily, many of them for depression, pain, or to stay off opioids, face abrupt discontinuation of a mu-opioid receptor agonist. The agencies' own documents describe the resulting withdrawal as opioid-like and difficult to tolerate. There is no clinician who can legally prescribe a taper, no approved product to transition to, and no guidance in the proposed rule. The people at highest risk are exactly the ones the rule is nominally meant to protect.

2. The research that would answer every open question gets harder at the moment it's needed most

Schedule I registration adds security requirements, storage rules, quotas, inspection, and years of administrative delay. Two US programs have already stopped, one for recruitment and one for a missed endpoint. A third will now be dramatically more expensive to start. The classification rests partly on the absence of US clinical data, and then makes generating US clinical data significantly harder. Patients pay for that loop, because the questions about who benefits, at what dose, in what formulation, stay unanswered indefinitely.

3. People who can't tolerate SSRIs lose a mechanistically different option

This matters more than it sounds. The reason people abandon SSRIs is usually not that they don't work at all, it's sexual dysfunction, weight gain, and emotional blunting. Tianeptine's human trial data, including Kasper and Olié's meta-analysis against SSRIs, Bonierbale's sexual function work, and Emsley's 2018 escitalopram-controlled study, show comparable efficacy without that side effect burden. It also works through an entirely different mechanism than every antidepressant approved in the US. For treatment-resistant patients, mechanism diversity is not a luxury. It's the whole strategy. Schedule I removes an option that is already prescribed to millions of people elsewhere.

4. Neuropathic pain patients lose an active research lead, not a hypothetical one

Serafini and colleagues at Mount Sinai showed in 2023 that tianeptine produces lasting relief of mechanical allodynia in the spared nerve injury model, with faster onset than desipramine and without the analgesic tolerance or withdrawal that limits opioids. That's preclinical, and it should be labeled as preclinical. But there is also a completed randomized controlled trial in humans comparing tianeptine to pregabalin for post-mastectomy pain syndrome. That is a real signal in a population with poor options, and Schedule I ends the follow-up work that would confirm or refute it.

5. Fibromyalgia patients lose an option that was already tested in a real trial

There is a completed randomized, double-blind, placebo-controlled trial of tianeptine in fibromyalgia, registered prospectively in 2006, run at Clínica CIMA in Barcelona under Prof. García-Fructuoso, using 12.5 mg three times daily against identical placebo, with pain VAS and FIQ as primary outcomes at 24 weeks. Results were never published, which is its own problem, but the trial happened. There is also preclinical work: Lee and colleagues showed in 2017 that tianeptine reversed pain sensitivity in a restraint-and-cold-stress fibromyalgia model and restored BDNF and phospho-CREB in the medial prefrontal cortex and hippocampus, which is a mechanistically coherent story for a condition driven by stress-related central sensitization.

Neither the DEA eight-factor analysis nor the HHS Basis for Recommendation contains the word fibromyalgia. Not once. Neither contains the phrase chronic pain. For a population with a short list of partially effective drugs, the agencies proposed the most restrictive schedule in federal law without acknowledging that this line of research exists.

6. A non-opioid compound for Alzheimer's and Parkinson's gets swept in by accident

The rule schedules all isomers of tianeptine. One of them, estianeptine, is in preclinical development by US company Tonix specifically because it lacks mu-opioid receptor activity while keeping the neuroplasticity effects. Mu-opioid activity is the entire basis for the scheduling. So a compound without the property being regulated inherits Schedule I status, and a program aimed at neurodegenerative disease absorbs the full research burden for no stated reason. Nobody analyzed this. The word "isomer" appears in DEA's document only in boilerplate.

7. It pushes people toward more dangerous substances and a more dangerous supply

The people using tianeptine to manage opioid withdrawal or chronic pain don't stop needing something on the effective date. Some will go back to opioids. Others will move to whatever is next in the unregulated market, which is how we got here in the first place. Meanwhile the products that actually caused the US poisonings, like Neptune's Fix, were dangerous because they contained undisclosed synthetic cannabinoids, not because tianeptine was legal to sell. Criminalizing possession doesn't clean up those bottles. It does make people less likely to tell an emergency physician what they took, and less likely to tell a clinician they're using it at all. Both of those cost lives.

Here's what bothers me about the DEA trying to make tianeptine a Schedule 1 drug

None of these people are who the rule is aimed at. The gas station products that started this are already illegal to sell. FDA already has the authority to pull them, and has used it. Scheduling doesn't clean up a single bottle of adulterated elixir.

What it does do is criminalize the people who were already managing something, shut down the trials that would tell us who actually benefits, and cut off people who are physically dependent with no taper and no doctor who can legally help them. Those aren't unintended consequences. Those are the main things this rule will accomplish.

I live with fibromyalgia. I've had hundreds of thousands of conversations with people in chronic pain, and I can tell you what happens when you take an option off the table without putting one back. People don't stop hurting. They just stop telling anyone what they're taking.

We should be studying this compound, not burying it. Please follow the science, not fear.

COMMENT BY AUGUST 7, 2026 to stop the Schedule 1 ban

The comment period on this proposed rule closes August 7, 2026.

If you're a patient, a clinician, or a researcher who has seen what this compound does in a body that's run out of other options, the federal register listing is where that record gets built. Also if you believe that we should be researching medicines, not adding them to a felony list, please comment.

Silence reads as consensus. Don't let it. COMMENT TODAY.